Silence Therapeutics plc SLNCF
OTC · OOTC · stock · Pharmaceutical Preparations
1/9
Piotroski F — financial health
-12.42
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $559,000 | -$88.6M | $344,000 | -$62.3M | $62.3M |
| 2024 | $43.3M | -$45.3M | $31.4M | -$67.9M | $134.0M |
| 2023 | $31.6M | -$54.2M | $18.8M | -$49.5M | $22.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.42 (distress)
- Working capital / assets 0.799
- Retained earnings / assets -4.28
- EBIT / assets -0.693
- Equity / liabilities 0.901
Source: SEC EDGAR filings · CIK 0001479615 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.